About ALGS

Founded: 2018
Employees: 82
CEO: Lawrence Blatt
WebsiteView website: www.aligos.com

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Recent ALGS News & Updates

Announcement • Aug 14

Aligos Therapeutics Initiates Dosing in Phase 1 Study of Alg-170675 for Chronic Hepatitis B Virus Infection

Aligos Therapeutics, Inc. announced that dosing has been initiated in the Phase 1 study of ALG-170675, an investigational next-generation antisense oligonucleotide (ASO) being evaluated for functional cure in the treatment of chronic hepatitis B virus (HBV) infection. The study is being conducted in China by Xiamen Amoytop Biotech Co. Ltd. (“Amoytop”), who maintain rights in Greater China. ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activation. Single and multiple ascending doses are planned. The study will allow rapid advancement into participants with chronic HBV infection in the Fourth Quarter 2026. ALG-170675 was designed as a next-generation antisense oligonucleotide with the potential to enhance functional cure rates for patients living with chronic HBV infection, and its advancement into clinical development represents an important step toward that goal. ALG-170675 is a next-generation ASO discovered by Aligos as part of a research collaboration with Amoytop, who retain rights in Greater China. Novel intellectual property has been filed for this drug candidate, which has shown improved RNase H mediated in vivo activity over GSK-836 (bepirovirsen) with similar hTLR8 agonist activity observed in vitro and in vivo. In addition, ALG-170675 utilizes novel monomers that could potentially reduce ASO toxicity and improve ASO liver to kidney ratios. The Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG-170675 following single (SAD) and multiple (MAD) ascending doses. The SAD portion plans to enroll approximately 32 healthy participants across four dose cohorts of 75 mg, 150 mg, 300 mg, and 450 mg. Following completion of the 300 mg SAD cohort, the MAD portion of the study is expected to begin and would enroll approximately 24 healthy participants. The study design also includes a cohort of approximately 16 participants with chronic HBV infection, which is expected to initiate following completion of the 150 mg MAD cohort in the Fourth Quarter 2026.

Recent updates

No updates

Aligos Therapeutics, Inc. Stock Price

ALGS Share Price Performance

ALGS Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Aligos Therapeutics, Inc. Key Details

About ALGS

Recent ALGS News & Updates

Aligos Therapeutics Initiates Dosing in Phase 1 Study of Alg-170675 for Chronic Hepatitis B Virus Infection

Consensus revenue estimates increase by 68%

Industry Analysts Just Made A Stunning Upgrade To Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts

Recent updates

Aligos Therapeutics, Inc. Competitors

Oncolytics Biotech

Tenax Therapeutics

Entasis Therapeutics Holdings

Pelthos Therapeutics